Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued?

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

Acaster Lloyd Consulting Ltd and Oxford PharmaGenesis received funding from Novartis Pharma AG.

Author contributions:

A.L., H.S. and N.A. drafted the manuscript, critically reviewed all versions and approved the final version.

Declaration of financial/other relationships

A.L. has disclosed that he is an employee of Acaster Lloyd Consulting Ltd, London, UK. H.S. has disclosed that she is a paid employee of Oxford PharmaGenesis, Oxford, UK. N.A. has disclosed that he is a paid employee of Novartis Pharma AG, Basel, Switzerland. CMRO peer reviewers on this manuscript have received an honorarium from CMRO for their review work but have no relevant financial or other relationships to disclose.

Acknowledgements

The authors thank John Findlay at Oxford PharmaGenesis, Oxford, UK for medical writing support.